BLU-554|BLU554|FGFR4 inhibitor

BLU-554|BLU554|FGFR4 inhibitor

BLU-554 is an isoform selective inhibitor of fibroblast growth factor (FGF) receptor 4 (FGFR4; CD334)

Product Name: BLU-554 (FGFR4 inhibitor)|Cat No. DC9791|CAS: 1707289-21-1|Other names:BLU-554,BLU554,BLU 554|MW: 503.38|Molecule Formular: C24H24Cl2N4O4|Purity>98%

BLU-554 targets the fibroblast growth factor receptor 4 (FGFR4), while sparing other members of the FGFR family and showing little to no inhibition of all other kinases. Aberrant signaling of FGFR4 is a key driver in up to 30 percent of HCC, and BLU-554 has shown significant anti-tumor activity, including complete and sustained tumor regression, in preclinical models of HCC. Initial clinical development will target aberrant FGFR4 activation in HCC and will assess the safety and preliminary efficacy of BLU-554 in treatment-naïve HCC patients and patients that have failed sorafenib, the only approved systemic therapy for HCC.